Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
© Okabe et al.; licensee BioMed Central Ltd. 2013
Received: 7 September 2012
Accepted: 18 February 2013
Published: 4 April 2013
The use of imatinib, an ABL tyrosine kinase inhibitor, has led to a dramatic change in the management of BCR-ABL-positive leukemia patients. However, resistance to imatinib mediated by mutations in the BCR-ABL domain has become a major problem in the treatment of these patients.
In the present study, we examined the activity of histone deacetylase (HDAC) inhibitors in combination with an Aurora kinase inhibitor in BCR-ABL-expressing cells.
We found the HDAC inhibitors vorinostat and/or pracinostat (SB939) induced apoptosis in BCR-ABL-expressing cells. Additionally, HDAC inhibitors reduced levels of Aurora A and B protein. An Aurora kinase inhibitor, tozasertib (VX-680), inhibited growth, promoted pro-apoptotic activity, reduced the phosphorylation of BCR-ABL and Crk-L, and activated caspase-3 and poly (ADP-ribose) polymerase (PARP) in BCR-ABL-positive cells. Moreover, after treatment with tozasertib, HDAC protein expression was decreased. Combination of vorinostat or pracinostat with tozasertib had a synergistic inhibitory effect on the proliferation of T315I cells. Phosphorylation of Crk-L decreased, and PARP activation increased after treatment with vorinostat or pracinostat and tozasertib. Moreover, combination of vorinostat or pracinostat and tozasertib significantly increased the extent of apoptosis in primary chronic myeloid leukemia cells.
This study demonstrated that combination of HDAC and Aurora inhibitors was highly effective against BCR-ABL-expressing cells.
KeywordsHDAC inhibitor Aurora kinase inhibitor T315I mutation
Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by unregulated proliferation of predominantly myeloid cells in the bone marrow . BCR-ABL fusion proteins resulting from the chromosomal translocation t(9;22) (the Philadelphia chromosome: Ph) cause CML . BCR-ABL activity leads to uncontrolled cell proliferation, reduced apoptosis, and malignant expansion of hematopoietic stem cell populations. The ABL tyrosine kinase inhibitor (TKI) imatinib has dramatically improved the management and prognosis of patients with CML . However, some patients, particularly those with advanced-phase CML, have developed resistance to imatinib . More than 50 distinct point mutations in the kinase domain of BCR-ABL have been detected in patients with imatinib-resistant CML; point mutations in this domain are the most frequent cause of acquired imatinib resistance in CML patients [5, 6]. Second-generation TKIs, such as dasatinib and nilotinib, have shown promising results in imatinib-resistant CML patients, but dasatinib and nilotinib are not effective against CML clones with T315I mutations . Recently, ponatinib (also known as AP24534) was identified as a potent oral tyrosine kinase inhibitor and was shown to block native and mutated BCR-ABL. Ponatinib is highly active in patients with Ph-positive leukemias, including those with BCR-ABL T315I mutations . However, alternative strategies against point mutations (i.e., T315I) within the BCR-ABL kinase domain are still important to improve the prognosis of CML patients.
Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are enzymes that regulate chromatin structure and function . Modification of histones (e.g., via histone acetylation and deacetylation) plays an important role in the regulation of gene expression . Increased expression of HDACs and disrupted activities of HATs have been observed in several tumor types . HDAC inhibitors are emerging as potent antitumor agents that induce cell cycle arrest, differentiation, and apoptosis in many tumor cells of different origins. HDAC inhibitors represent a new and promising class of antitumor drugs . HDAC inhibitors influence gene expression by enhancing histone acetylation. Because HDAC inhibitors regulate many signaling pathways, cotreatment of HDAC inhibitors with molecular targeted drugs, such as Aurora kinase inhibitors, is a promising strategy against many types of tumors.
This study aimed to examine the activity of the HDAC inhibitors vorinostat and pracinostat (SB939) in vitro, both alone and in combination with an Aurora kinase inhibitor. This study also explored the molecular mechanisms underlying treatment-related cell growth inhibition and apoptosis in BCR-ABL-expressing cell lines with point mutations. We found that the combination of HDAC and Aurora kinase inhibitors significantly inhibited cell growth in BCR-ABL-expressing cells.
Results and discussion
Activity of HDAC inhibitors in BCR-ABL-positive cells
Analysis of the effects of an Aurora kinase inhibitor on intracellular signaling in K562 cells
Activity of the Aurora kinase inhibitor in wild-type and mutant BCR-ABL-expressing cells
Efficacy of cotreatment with HDAC and Aurora kinase inhibitors in BCR-ABL-expressing cells
Efficacy of cotreatment with HDAC and Aurora kinase inhibitors in BCR-ABL-positive primary CML cells
In the current study, HDAC inhibitors induced apoptosis in BCR-ABL-positive leukemia cells. In particular, profound inhibition of cell growth and induction of apoptosis were observed in response to HDAC inhibitors in BCR-ABL-positive K562 and mouse pro-B Ba/F3 cells with ectopic expression of wt and mutant T315I. This response was amplified by cotreatment with an Aurora kinase inhibitor. In this study, we also demonstrated that Aurora kinase proteins were degraded by vorinostat or pracinostat in a dose-dependent manner (Figure 1B). Although the levels of Aurora family proteins were not directly reduced by tozasertib treatment, tozasertib inhibited the expression of HDAC proteins (Figure 2A). As such, our data indicated that vorinostat or pracinostat and tozasertib affected the activities of both Aurora kinase and HDAC, in turn increasing antitumor activity in this system. Clinical trials using tozasertib have been discontinued. However, other pan-Aurora/BCR-ABL dual inhibitors may exhibit a similar profile, and these continue to be studied clinically. Our findings suggest that cotreatment with these compounds and specific molecular-targeted drugs could benefit patients with leukemic BCR-ABL cells that are resistant to more conventional treatments.
Reagents and antibodies
The HDAC inhibitors vorinostat (SAHA, suberoylanilide hydroxamic acid) and pracinostat (SB939) were provided by Selleck Chemicals LLC (Houston, TX). Tozasertib (VX-680, MK-0457) was kindly donated by Vertex Pharmaceuticals Inc (Cambridge, MA). Stock solutions of vorinostat, pracinostat, and tozasertib were dissolved in dimethyl sulfoxide and subsequently diluted to the desired concentration in growth medium. Anti-phospho-Abl, -phospho-Crk-L, -cleaved caspase 3, -PARP-HDAC1, -HDAC2, -HDAC5, -HDAC7, -Bim, and -Aurora A and B antibodies (Abs) were obtained from Cell Signaling Technology (Beverly, MA). Other reagents were obtained from Sigma (St. Louis, MO).
The human CML cell line K562 was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Ba/F3 wt-BCR-ABL cells and Ba/F3 T315I cells were described previously . These cells were maintained in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum with 1% penicillin/streptomycin in a humidified incubator at 37°C.
Cell proliferation assay
Cell proliferation analysis was performed as previously described .
Cell signaling assays and western blot analysis
Panorama Ab microarrays (Sigma) were analyzed according to the manufacturer’s instructions. The arrays were scanned using a GenePix Personal 4100A microarray scanner, and normalization was carried out using the housekeeping protein included with the chip. The protein expression ratio was calculated using MS Excel. Western blot analysis was performed as previously described [26, 27].
DNA microarray and microarray data analysis
DNA microarray analysis was performed as previously described . In brief, K562 cells were treated with 1 μM tozasertib for 16 h. Following incubation at 37°C, the cells were washed twice with ice-cold phosphate-buffered saline (PBS) and collected immediately for RNA isolation. In this study, we used the Human Genome U133A Genechip (Affymetrix Santa Clara, CA), which contains more than 47,000 transcripts. Target preparation was carried out following the manufacturer’s expression analysis manual. All arrays were screened for quality by standard methods, and the mean fluorescent intensity for each probe set was determined.
This study was approved by the Institutional Review Board of Tokyo Medical University, and informed consent was provided by all patients in accordance with the Declaration of Helsinki. Primary samples were obtained from the peripheral blood of CML patients. Mononuclear cells were isolated from blood samples and separated by Lymphosepar (Immuno-Biological Laboratories Co., Gunma, Japan). The cells were cultured in RPMI1640 medium containing 10% fetal calf serum and analyzed as described.
Flow cytometory analysis
Cells were treated with the indicated concentrations of tozasertib for 48 h. Annexin V/propidium iodide apoptosis assays were performed according to the manufacturer’s instructions (Beckman Coulter, Inc., Brea, CA). The cells were gently mixed and immediately analyzed by flow cytometry.
Differences between treatment groups, in terms of dose response and apoptosis, were determined using Student’s t test. P values of less than 0.05 were considered significant.
This work was supported by a High-Tech Research Center Project for private universities, a matching fund subsidy from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), and by the University-Industry Joint Research Project for private universities, a matching fund subsidy from MEXT. This work was also supported by Grants-in-Aid for Scientific Research from MEXT.
- Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN: Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest. 1978, 62: 813-815.View ArticleGoogle Scholar
- Goldman JM, Melo JV: BCR-ABL in chronic myelogenous leukemia–how does it work?. Acta Haematol. 2008, 119: 212-217. 10.1159/000140633.View ArticlePubMedGoogle Scholar
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346: 645-652. 10.1056/NEJMoa011573.View ArticlePubMedGoogle Scholar
- Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J: New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006, 145: 913-923. 10.7326/0003-4819-145-12-200612190-00008.View ArticlePubMedGoogle Scholar
- Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002, 16: 2190-2196. 10.1038/sj.leu.2402741.View ArticlePubMedGoogle Scholar
- Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005, 103: 1659-1669. 10.1002/cncr.20922.View ArticlePubMedGoogle Scholar
- Quintás-Cardama A, Kantarjian H, Cortes J: Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol. 2010, 47: 371-380. 10.1053/j.seminhematol.2010.06.004.View ArticlePubMedGoogle Scholar
- Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M: Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012, 367: 2075-2088. 10.1056/NEJMoa1205127.PubMed CentralView ArticlePubMedGoogle Scholar
- Hodawadekar SC, Marmorstein R: Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene. 2007, 26: 5528-5540. 10.1038/sj.onc.1210619.View ArticlePubMedGoogle Scholar
- Yang XJ, Seto E: HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007, 26: 5310-5318. 10.1038/sj.onc.1210599.View ArticlePubMedGoogle Scholar
- Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene. 2007, 26: 5420-5432. 10.1038/sj.onc.1210610.View ArticlePubMedGoogle Scholar
- Carew JS, Giles FJ, Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269: 7-17. 10.1016/j.canlet.2008.03.037.View ArticlePubMedGoogle Scholar
- Novotny-Diermayr V, Sausgruber N, Loh YK, Pasha MK, Jayaraman R, Hentze H, Yong WP, Goh BC, Toh HC, Ethirajulu K, Zhu J, Wood JM: Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue. Mol Cancer Ther. 2011, 10: 1207-1217. 10.1158/1535-7163.MCT-11-0044.View ArticlePubMedGoogle Scholar
- Okabe S, Tauchi TA, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K: Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev. 2007, 16: 503-514. 10.1089/scd.2007.9994.View ArticlePubMedGoogle Scholar
- Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene. 2007, 26: 1351-1356. 10.1038/sj.onc.1210204.View ArticlePubMedGoogle Scholar
- Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL, Hsiao PW: Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res. 2009, 15: 840-850. 10.1158/1078-0432.CCR-08-1918.View ArticlePubMedGoogle Scholar
- Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004, 10: 262-267. 10.1038/nm1003.View ArticlePubMedGoogle Scholar
- Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G: GIMEMA Working Party on Chronic Myeloid Leukemia: Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006, 12: 7374-7379. 10.1158/1078-0432.CCR-06-1516.View ArticlePubMedGoogle Scholar
- Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood. 2007, 110: 727-734. 10.1182/blood-2006-11-052373.View ArticlePubMedGoogle Scholar
- Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.View ArticlePubMedGoogle Scholar
- Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G: Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011, 67: 305-314. 10.1007/s00280-010-1318-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Yong WP, Goh BC, Soo RA, Toh HC, Ethirajulu K, Wood J, Novotny-Diermayr V, Lee SC, Yeo WL, Chan D, Lim D, Seah E, Lim R, Zhu J: Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol. 2011, 22: 2516-2522. 10.1093/annonc/mdq784.View ArticlePubMedGoogle Scholar
- Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ: Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 2010, 28: 4507-4512. 10.1200/JCO.2010.30.2307.PubMed CentralView ArticlePubMedGoogle Scholar
- Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005, 106: 3948-3954. 10.1182/blood-2005-06-2209.View ArticlePubMedGoogle Scholar
- Okabe S, Tauchi T, Ohyashiki K: Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2008, 14: 6181-6186. 10.1158/1078-0432.CCR-08-0461.View ArticlePubMedGoogle Scholar
- Okabe S, Tauchi T, Ohyashiki K, Broxmeyer HE: Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45. Blood Cells Mol Dis. 2006, 36: 308-314. 10.1016/j.bcmd.2005.12.035.View ArticlePubMedGoogle Scholar
- Okabe S, Fukuda S, Kim YJ, Niki M, Pelus LM, Ohyashiki K, Pandolfi PP, Broxmeyer HE: Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. Blood. 2005, 105: 474-480. 10.1182/blood-2004-03-0843.View ArticlePubMedGoogle Scholar
- Okabe S, Tauchi T, Ohyashiki JH, Ohyashiki K: Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. Biochem Biophys Res Commun. 2009, 380: 775-779. 10.1016/j.bbrc.2009.01.141.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.